TechConnect


Stopping a Moving Target: Novel 'Blue' Compound Halts Tumor Spread, Improves Brain Cancer Treatment in Animal Studies

March 22, 2013 09:16 AM EST By: Jennifer Rocha

Researchers from the Georgia Institute of Technology and Emory University have designed the new treatment approach

Story content courtesy of Georgia Institute of Technology, US

The researchers treated animals possessing an invasive tumor with a vesicle carrying a molecule called imipramine blue, followed by conventional doxorubicin chemotherapy. The tumors ceased their invasion of healthy tissue and the animals survived longer than animals treated with chemotherapy alone.

The research was supported primarily by the Ian’s Friends Foundation and partially by the Georgia Cancer Coalition, the Wallace H. Coulter Foundation and a National Science Foundation graduate research fellowship.

Jack Arbiser, a professor in the Emory University Department of Dermatology, designed the novel imipramine blue compound, which is an organic triphenylmethane dye.

 

Subscribe to our mailing list, and we'll keep you posted of the latest developments.

RSS feed of TechConnect News™ RSS feed of TechConnect News™

Annual Meeting

TechConnect World 2014
Washington, DC, June 15-18, 2014
 

Event Spotlight

NISS 2014
Washington, DC, June 15-18, 2014
NSBIRC 2014
Washington, DC, June 16-18, 2014
APCE 2014
Honolulu, Hawaii, September 15-17, 2014
DES
Austin, TX, November 11-14, 2014


© TechConnect. All Rights Reserved. Disclaimer
Terms of Use | Privacy Policy | Contact Us | Site Map